Kent Imaging has expanded its Snapshot range with SnapshotGLO
Kent Imaging, a provider of diagnostic imaging solutions, has expanded its Snapshot range with SnapshotGLO.
SnapshotGLO is a handheld, portable device that brings bacterial autofluorescence technology to the point of care so that clinicians can detect bacterial bioburden, guide treatment decisions, and improve patient outcomes.
The device is capable of capturing fluorescence images that highlight areas of potential bacterial presence, an insight not visible in a standard examination. It can identify regions where bacterial loads exceed 10⁴CFU/g and presents a clinical image for wound detection, segmentation, and sizing.
Clinicians can view and digitally record high-resolution clinical and fluorescence images, making documentation consistent and creating a means of visually tracking wound progression over a period.
Pierre Lemire, CEO of Kent Imaging, said, “With the launch of SnapshotGLO, we’re expanding the Snapshot family to provide clinicians with additional powerful tools at the point of care. This new innovation complements our flagship SnapshotNIR oxygenation imaging device and builds on our mission to improve patient outcomes by delivering actionable imaging that helps clinicians detect, direct, and protect. SnapshotGLO provides another critical tool in the fight against hard-to-heal wounds, helping healthcare providers make a meaningful difference in their patients’ healing journey.”
“With the ability to capture bacterial fluorescence images with SnapshotGLO, clinicians can identify regions where bacterial loads exceeding 10⁴CFU/g, which supports targeted interventions, especially in cases where clinical signs of infection may be challenging to manage,” commented Jason Nessler, Vice President of Product Development at Kent Imaging. “The Snapshot device family offers clinicians dual-modality insights that enhance clinical decision making at the point of care.”
SnapshotGLO uses autofluorescence imaging, allowing it to detect native fluorescence that bacterial compounds emit when exposed to excitation light, identifying bacterial loads exceeding 10⁴CFU/g even when no systemic signs or symptoms are present.
Dr Jeffrey Niezgoda, chief medical officer of Wound Care and Limb Preservation at Kent Imaging, said, “Chronic wounds remain a leading cause of preventable amputations, often driven by undetected or mismanaged bacterial burden. SnapshotGLO gives clinicians a powerful new option to visualise bacterial fluorescence and measure wounds in real time. By identifying signs of infection earlier and supporting more informed treatment decisions, we can reduce infections, preserve limbs, and ultimately enhance quality of life for patients living with chronic wounds.”
Dr Glyn Jones, chief medical officer of Surgery at Kent Imaging, said, “SnapshotGLO brings a new level of insight to wound assessment. It enables surgeons to visualise bacterial presence and track healing with precision. This is extremely valuable in surgical cases, where every stage of healing is critical—from surgical site integrity to post-operative infection prevention.”
SnapshotGLO can simultaneously capture a clinical and an unfiltered fluorescence image, producing an immediate, side-by-side comparison so clinicians can evaluate visible wound characteristics alongside bioburden indicators.
Dr Tyler Sexton, MD, MAPWCA, CHWS, CMO Brevard Regional Hyperbaric and Wound Centre, TrueHyperbarRx, CoastalHyperbaRx & Precision Hyperbarics, as a user of both SnapshotGLO and SnapshotNIR, said, “Effective wound care starts with proper wound bed preparation."
“SnapshotGLO allows me to visualise the bioburden and bacteria in a wound, helping me target debridement precisely. When combined with SnapshotNIR, I can also confirm and document tissue viability, ensuring the wound bed is fully prepared for healing. Together, these technologies elevate both the science and the outcomes of advanced wound care centers.”
